This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial.
Aged 18-65 years old, including the boundary value, no gender restriction;
Subjects meeting the 2016 ACR/EULAR classification criteria for Sjögren's syndrome, and also meet the diagnostic criteria for ocular involvement.
The ocular involvement symptoms and signs of these patients cannot be relieved after at least 3 months of conventional therapy, including artificial tears and topical or systemic corticosteroids.
Extra-ocular manifestations of Sjögren's syndrome clinically stable.
Known allergy to any component of the investigational drug.
Active ocular infection.
Presence of other significant ocular disease or trauma diagnosed prior to enrollment, including but not limited to glaucoma, uveitis, retinopathy, chemical injury, or thermal burns.
History of any ocular surgery within the preceding 6 months, including cataract surgery.